Top

Journal of Neurology

Published in:

19-10-2023 | Letter to the Editors

Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutières syndrome

Authors: Jenae Vancura, Natalie K. Boyd, Benjamin N. Vogel, Deepti Nagesh, Eugenia Ho, Jonathan D. Santoro

Published in: Journal of Neurology | Issue 2/2024

Excerpt

Dear Sirs, …

Rice GI, Bond J, Asipu A et al (2009) Mutations involved in aicardi-goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 41:829–832. https://doi.org/10.1038/ng.373CrossRefPubMedPubMedCentral

Crow YJ (2005) Aicardi-goutières syndrome. In: Adam MP, Mirzaa GM, Pagon RA (eds) GeneReviews®. University of Washington, Seattle, Seattle (WA)

Crow YJ, Vanderver A, Orcesi S, Kuijpers TW, Rice GI (2014) Therapies in aicardi-goutières syndrome. Clin Exp Immunol 175(1):1–8. https://doi.org/10.1111/cei.12115CrossRefPubMed

Crow YJ, Manel N (2015) Aicardi-Goutières syndrome and the type I interferonopathies. Nat Rev Immunol 15(7):429–440. https://doi.org/10.1038/nri3850CrossRefPubMed

Garau J, Cavallera V, Valente M et al (2019) Molecular genetics and interferon signature in the italian aicardi goutières syndrome cohort: report of 12 new cases and literature review. J Clin Med 8(5):750. https://doi.org/10.3390/jcm8050750CrossRefPubMedPubMedCentral

Rice GI, Forte GM, Szynkiewicz M et al (2013) Assessment of interferon-related biomarkers in aicardi-goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol 12(12):1159–1169. https://doi.org/10.1016/S1474-4422(13)70258-8CrossRefPubMedPubMedCentral

Brar JS, Verma R, Al-Omari M, Siu VM, Andrade AV, Jurkiewicz MT, Lalgudi Ganesan S (2022) Moyamoya syndrome in an infant with aicardi-goutières and williams syndromes: a case report. Neuropediatrics 53(3):204–207. https://doi.org/10.1055/s-0041-1739131CrossRefPubMed

Barrit S (2018) Syndrome d’aicardi-goutières associé à un quasi-Moyamoya par une mutation biallélique de SAMHD1 [An aicardi-goutières syndrome associated with a quasi-moyamoya by a biallelic mutation in SAMHD1]. Rev Med Brux 39(3):155–160. https://doi.org/10.30637/2018.16-030CrossRefPubMed

Smith ER, Scott RM (2005) Surgical management of moyamoya syndrome. Skull Base 15(1):15–26. https://doi.org/10.1055/s-2005-868160CrossRefPubMedPubMedCentral

10.

Ramesh V, Bernardi B, Stafa A et al (2010) Intracerebral large artery disease in aicardi-goutières syndrome implicates SAMHD1 in vascular homeostasis. Dev Med Child Neurol 52:725–732. https://doi.org/10.1111/j.1469-8749.2010.03727.xCrossRefPubMed

11.

Vanderver A, Adang L, Gavazzi F et al (2020) Janus kinase inhibition in the aicardi-goutières syndrome. N Engl J Med 383(10):986–989. https://doi.org/10.1056/NEJMc2001362CrossRefPubMedPubMedCentral

12.

Cuadrado E, Michailidou I, van Bodegraven EJ, Jansen MH, Sluijs JA, Geerts D, Couraud PO, De Filippis L, Vescovi AL, Kuijpers TW, Hol EM (2015) Phenotypic variation in aicardi-goutières syndrome explained by cell-specific IFN-stimulated gene response and cytokine release. J Immunol 194(8):3623–3633. https://doi.org/10.4049/jimmunol.1401334CrossRefPubMed

13.

Ahmad A, Zaheer M, Balis FJ (2022) Baricitinib StatPearls. StatPearls Publishing, Treasure Island (FL)

14.

Sanchez GAM, Reinhardt A, Ramsey S et al (2018) JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest 128(7):3041–3052. https://doi.org/10.1172/JCI98814CrossRefPubMedPubMedCentral

15.

Wallace DJ, Furie RA, Tanaka Y et al (2018) Baricitinib for systemic lupus erythematosus: a double-blind, randomized, placebo-controlled, phase 2 trial. Lancet 392(10143):222–231. https://doi.org/10.1016/S0140-6736(18)31363-1CrossRefPubMed

Title: Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutières syndrome
Authors: Jenae Vancura
Natalie K. Boyd
Benjamin N. Vogel
Deepti Nagesh
Eugenia Ho
Jonathan D. Santoro
Publication date: 19-10-2023
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 2/2024
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-12040-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutières syndrome

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2024

Intake reminders are effective in enhancing adherence to direct oral anticoagulants in stroke patients: a randomised cross-over trial (MAAESTRO study)

Mitochondrial myopathy without extraocular muscle involvement: a unique clinicopathologic profile

Multiple sclerosis in the elderly: a retrospective cohort study

Machine learning using multimodal and autonomic nervous system parameters predicts clinically apparent stroke-associated pneumonia in a development and testing study

Recurrence and long-term outcomes of Tolosa-Hunt syndrome

High serum uric acid levels are protective against cognitive impairment in amyotrophic lateral sclerosis